Interleukin-1-beta inhibitor - AventisAlternative Names: IL-1-beta antagonist - Aventis; IL-1-beta inhibitor - Aventis; Interleukin-1-beta antagonist - Aventis
Latest Information Update: 04 Jul 2002
At a glance
- Originator Aventis
- Mechanism of Action Interleukin 1 beta inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 11 Jul 2000 Preclinical development for Rheumatoid arthritis (Unknown route)